Ubrogepant Reduces Migraine Pain and Most Bothersome Symptom vs Placebo

Ubrogepant (Ubrelvy) demonstrated efficacy in the acute treatment of migraine, according to results from the ACHIEVE II randomized clinical trial published on 2019-01-01 in JAMA. The study found that ubrogepant significantly reduced both migraine pain and the most bothersome associated symptom compared to placebo.

Background

Migraine is a common and often debilitating neurological condition characterized by severe headaches, often accompanied by symptoms such as nausea, vomiting, and sensitivity to light and sound. Effective acute treatments are crucial for managing these attacks, which can significantly impact a patient's quality of life. Ubrogepant is an oral medication developed for the acute treatment of migraine. The ACHIEVE II trial was conducted to evaluate its efficacy, safety, and tolerability in this patient population.

Trial design

The ACHIEVE II was a randomized clinical trial designed to investigate the effect of ubrogepant compared to placebo in the acute treatment of migraine. The study's primary objectives included assessing the impact of the drug on pain and the most bothersome associated symptom experienced during a migraine attack, aiming to provide evidence for its clinical utility.

Key results

The ACHIEVE II trial demonstrated that ubrogepant was effective in reducing migraine pain and the most bothersome associated symptom when used for the acute treatment of migraine, compared to placebo. These findings support the clinical utility of ubrogepant in managing acute migraine attacks.

What this means

The publication of the ACHIEVE II trial results provides important evidence for the role of ubrogepant as an oral treatment option for acute migraine. For clinicians, researchers, and patients, these findings suggest a new therapeutic approach for rapidly alleviating migraine symptoms. The demonstrated efficacy in reducing both pain and associated symptoms offers a significant benefit for individuals seeking relief from acute migraine episodes, potentially improving their ability to manage attacks effectively.

Source

The information regarding the ACHIEVE II trial was published in JAMA on 2019-01-01, as sourced from PubMed. The article is titled "Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial." The full publication is available via pubmed.ncbi.nlm.nih.gov.